This gene overview is brought to you as part of Tempus’ goal to inform providers about our genomic testing panels and the genes included in our offerings. Through our robust de-identified database of clinical information coupled with molecular testing results, we are capable of providing unique insights into these gene alterations. Many of the gene alterations reported on our somatic and germline panels are often key inclusion criteria for clinical trials.
The RAD51B gene is a member of the RAD51 family that functions in the homologous recombination repair (HRR) pathway. Loss of function mutations, copy number loss, and underexpression of RAD51B are associated with cancer progression.
RAD51B alterations in 10 most common cancers – Tempus database
FDA approved drugs for RAD51B mutated cancers
|Therapy||Tumor type (indication)||Biomarker|
|LYNPARZA® olaparib||Prostate cancer||HRR genes including RAD51B|
Some strategies in clinical trials for patients with RAD51B mutated cancers
|Mechanism||Phase 2||Phase 3|
|PARP inhibitors||rucaparib olaparib talazoparib||niraparib|
|ATR Kinase Inhibitor||VX-970 (M6620)|
View a more comprehensive list of clinical trials for patients with RAD51B mutated cancers. The Tempus TIME Trial® Program brings the right clinical trials to the right patients, in days instead of months. Learn how you can enroll today